Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Diabetes: Consensus Outlook

Product Code:
596200169
Last Updated:
January 2013
Format:
PDF + Excel
Price:
£3,485

Therapy Trends Consensus Outlook: Diabetes is an in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance. In addition, gain access to an interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017.

Key Features and Benefits

Report Features:

  • Historical diabetes sales from 2007–2012
  • Forecast diabetes sales from 2013-2017
  • Key competitors and drug developers
  • Current and late-stage pipeline drugs
  • Future event mapping to forecast data points
  • Expected impacting factors on global forecasts

Key Benefits:

  • Chart predicted market growth and product sales
  • Map your own market parameters
  • Tailor your strategic and investment focus
  • Assess your current and future sales resources
  • Set proactive launches and branding strategies

13 Analysts Compared

Barclays Capital Merrill Lynch
Credit Suisse Morgan & Stanley
Deutsche Bank Societe Generale
Goldman & Sachs Stifel Nicolaus
International Strategy & Investment UBS
Jefferies Wells Fargo
JP Morgan  

 

Product Forecasts Covered

Lantus (insulin glargine; Sanofi) Victoza (liraglutide; Novo Nordisk)
Levemir (insulin detemir; Novo Nordisk) Lyxumia (lixisenatide; Sanofi)
Tresiba (insulin degludec; Novo Nordisk) BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly)
Ryzodeg (degludecPlus; Novo Nordisk) Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca)
NovoRapid/NovoLog (insulin aspart; Novo Nordisk) Actos (pioglitazone; Takeda)
Humalog (insulin lispro; Eli Lilly) U300 (insulin glargine; Sanofi)
Apidra (insulin glulisine; Sanofi) LY2605541 (insulin peglispro; Eli Lilly)
NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim)
Januvia franchise (sitagliptin; Merck & Co) IDeglira (liraglutide + insulin degludec; Novo Nordisk)
Galvus franchise (vildagliptin; Novartis) Afrezza (Technosphere Insulin; MannKind Corporation)
Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) FIAsp (insulin aspart; Novo Nordisk)
Nesina franchise (alogliptin; Takeda) LY2189265 (dulaglutide; Eli Lilly)
Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences)
Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe)
Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin)  

 

Also Available: KOL Insight

Therapy Trends KOL Insight: Diabetes analyses the current and predicted key issues, current products and late-stage pipeline product and gives you qualitative information based on exclusive interviews with 12 key opinion leaders (KOLs) who are leading clinicians working in diabetes in the US and Europe.

Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed. Learn more.

To purchase the KOL Insight and Consensus Outlook module, click here.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved